Unnamed: 0,title,date,stock,sentiment
38202.0,Aeterna Zentaris Regains Compliance With Nasdaq Minimum Bid Price Requirement,2020-06-08 08:11:00-04:00,AEZS,neutral
38203.0,Aeterna Zentaris Announced That It Received A Positive Decision From The Listing Qualification Department Of Nasdaq,2020-06-04 16:08:00-04:00,AEZS,positive
38204.0,20 Healthcare Stocks Moving In Thursday's Pre-Market Session,2020-05-07 07:32:00-04:00,AEZS,neutral
38205.0,"AEterna Zentaris Q1 EPS $0.040 Up From $(0.300) YoY, Sales $1.100M Up From $37.000K YoY",2020-05-06 08:13:00-04:00,AEZS,neutral
38206.0,"The Daily Biotech Pulse: FDA Nod For UroGen, Novavax Coronavirus Vaccine To Enter Clinics, Soligenix Licenses Vaccine Adjuvant",2020-04-16 08:09:00-04:00,AEZS,neutral
38207.0,"Aeterna Zentaris Reports Receives Nasdaq Notice Of Non Compliance Related To $1/Share Minimum Bid Price Requirement; Co. Has Til Oct. 5, 2020 To Regain Compliance",2020-04-15 16:07:00-04:00,AEZS,neutral
38208.0,"Aeterna Zentaris Highlights Results In Dose-Finding Pediatric Study Of Macimorelin, Sees Planned Safety, Efficacy Study P02 Beginning Q4'20",2020-04-06 09:03:00-04:00,AEZS,positive
38209.0,"The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment",2020-03-11 08:03:00-04:00,AEZS,positive
38210.0,"The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index",2020-03-10 09:19:00-04:00,AEZS,negative
38211.0,"The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More",2020-03-03 07:51:00-05:00,AEZS,positive
38212.0,22 Healthcare Stocks Moving In Thursday's Pre-Market Session,2020-02-20 07:56:00-05:00,AEZS,neutral
38213.0,"The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study",2020-02-20 07:06:00-05:00,AEZS,negative
38214.0,Aeterna Zentaris Announces $4.5M Registered Direct Offering Priced At-The-Market; ~3.4M Shares Pirced @$1.29375/Share,2020-02-20 05:26:00-05:00,AEZS,positive
38215.0,Aeterna Zentaris Reports Completion Of Patient Recruitment In Dose-Finding Pediatric Study Of Macimorelin,2020-01-28 08:06:00-05:00,AEZS,neutral
38216.0,Aeterna Zentaris Regains Compliance With Nasdaq Minimum Bid Price Requirement For Continued Listing,2020-01-27 08:35:00-05:00,AEZS,neutral
38217.0,146 Biotechnology Stocks Moving In Thursday's Session,2020-01-23 12:47:00-05:00,AEZS,neutral
38218.0,98 Biotechnology Stocks Moving In Wednesday's Session,2020-01-22 13:33:00-05:00,AEZS,neutral
38219.0,64 Biggest Movers From Yesterday,2020-01-10 04:58:00-05:00,AEZS,neutral
38220.0,32 Stocks Moving In Thursday's Mid-Day Session,2020-01-09 12:08:00-05:00,AEZS,neutral
38221.0,"The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, DBV Announces Positive Peanut Allergy Study Findings, Applied Genetic Soars On Trial Results",2020-01-09 08:39:00-05:00,AEZS,positive
38222.0,20 Stocks Moving in Thursday's Pre-Market Session,2020-01-09 06:57:00-05:00,AEZS,neutral
38223.0,Aeterna Zentaris shares are trading lower after the company received a Nasdaq notice regarding the minimum bid price requirement.,2020-01-08 16:06:00-05:00,AEZS,neutral
38224.0,Aeterna Zentaris Receives NASDAQ Notification Regarding Minimum Bid Price Requirement,2020-01-08 16:02:00-05:00,AEZS,neutral
38225.0,"The Daily Biotech Pulse: Positive Adcom Verdict For Merck, Homology Medicine Slips On Mixed Gene Therapy Efficacy Data",2019-12-18 07:23:00-05:00,AEZS,positive
38226.0,"The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO",2019-12-17 07:56:00-05:00,AEZS,positive
38227.0,Stocks That Hit 52-Week Lows On Monday,2019-12-16 10:33:00-05:00,AEZS,negative
38228.0,"The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer",2019-12-13 08:10:00-05:00,AEZS,positive
38229.0,"The Daily Biotech Pulse: European Nod For Amgen, miRagen Overhauls Clinical Pipeline, Tonix Snags Patent Win",2019-12-12 07:38:00-05:00,AEZS,positive
38230.0,"The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares",2019-12-10 07:56:00-05:00,AEZS,positive
38231.0,"The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO",2019-10-10 07:31:00-04:00,AEZS,neutral
38232.0,"The Daily Biotech Pulse: FDA Approves Clinuvel Drug, Aclaris Files Patent Lawsuit Against Taro, Viela Out-Licenses Autoimmune Disorder Drug",2019-10-09 07:58:00-04:00,AEZS,negative
38233.0,Stocks That Hit 52-Week Lows On Tuesday,2019-10-08 12:02:00-04:00,AEZS,negative
38234.0,Aeterna Zentaris Announces Appointment of New President and Chief Executive Officer,2019-10-04 16:59:00-04:00,AEZS,neutral
38235.0,"The Daily Biotech Pulse: ESMO Conference Gets Underway, J&J's Darzalex Snags Another Approval, Kaleido Biosciences CFO To Leave",2019-09-27 07:56:00-04:00,AEZS,positive
38236.0,"The Daily Biotech Pulse: PhaseBio Leaps On Trial Results, Pacira Set To Join SmallCap 600 Index, Positive Readout For Amgen's Blood Cancer Drug",2019-09-25 07:13:00-04:00,AEZS,positive
38237.0,"The Daily Biotech Pulse: Sandoz Recalls Ulcer Drug, Anchiano Strikes Agreement With ADT Pharma, Proteon Announces Reverse Merger",2019-09-24 08:12:00-04:00,AEZS,positive
38238.0,Aeterna Zentaris Prices $5M Registered Direct Offering At $1.50/Unit,2019-09-20 11:04:00-04:00,AEZS,neutral
38239.0,70 Biggest Movers From Yesterday,2019-08-30 04:05:00-04:00,AEZS,neutral
38240.0,61 Biggest Movers From Yesterday,2019-08-15 05:57:00-04:00,AEZS,neutral
38241.0,48 Stocks Moving In Wednesday's Mid-Day Session,2019-08-14 12:50:00-04:00,AEZS,neutral
38242.0,AEterna Zentaris shares are trading higher after the company reported Q2 EPS and sales up from last year.,2019-08-13 16:17:00-04:00,AEZS,positive
38243.0,"AEterna Zentaris Q2 EPS $0.01 Up From $(0.16) YoY, Sales $194K Up From $168K YoY",2019-08-13 16:15:00-04:00,AEZS,neutral
38244.0,85 Biggest Movers From Yesterday,2019-08-07 05:39:00-04:00,AEZS,neutral
38245.0,68 Stocks Moving In Tuesday's Mid-Day Session,2019-08-06 13:55:00-04:00,AEZS,neutral
38246.0,46 Biggest Movers From Friday,2019-06-17 06:25:00-04:00,AEZS,neutral
38247.0,54 Biggest Movers From Yesterday,2019-06-14 05:02:00-04:00,AEZS,neutral
38248.0,38 Stocks Moving In Thursday's Mid-Day Session,2019-06-13 12:52:00-04:00,AEZS,neutral
38249.0,60 Biggest Movers From Friday,2019-06-10 06:41:00-04:00,AEZS,neutral
38250.0,44 Stocks Moving In Friday's Mid-Day Session,2019-06-07 12:50:00-04:00,AEZS,neutral
38251.0,55 Biggest Movers From Yesterday,2019-06-07 05:33:00-04:00,AEZS,neutral
38252.0,Aeterna Zentaris Announces Workforce Reduction,2019-06-06 14:07:00-04:00,AEZS,neutral
38253.0,95 Biggest Movers From Yesterday,2019-05-09 05:01:00-04:00,AEZS,neutral
38254.0,75 Stocks Moving In Wednesday's Mid-Day Session,2019-05-08 12:24:00-04:00,AEZS,neutral
38255.0,33 Stocks Moving In Wednesday's Pre-Market Session,2019-05-08 08:22:00-04:00,AEZS,neutral
38256.0,"AEterna Zentaris Q1 EPS $(0.3) Down From $0.87 YoY, Sales $37K Down From $24.658M YoY",2019-05-07 17:59:00-04:00,AEZS,neutral
38257.0,50 Biggest Movers From Yesterday,2019-04-12 05:22:00-04:00,AEZS,neutral
38258.0,"The Daily Biotech Pulse: Merrimack Pulls The Plug On Early-Stage Trial, Legal Headache For Novartis-Amgen Migraine Partnership",2019-04-05 07:48:00-04:00,AEZS,positive
38259.0,30 Stocks Moving In Wednesday's Pre-Market Session,2019-04-03 08:04:00-04:00,AEZS,neutral
38260.0,"The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial",2019-04-02 07:30:00-04:00,AEZS,neutral
38261.0,62 Biggest Movers From Friday,2019-04-01 04:46:00-04:00,AEZS,neutral
38262.0,AEterna Zentaris Q4 EPS $(0.31) Misses $(0.19) Estimate,2019-03-26 17:22:00-04:00,AEZS,negative
38263.0,"Earnings Scheduled For March 26, 2019",2019-03-26 04:00:00-04:00,AEZS,neutral
38264.0,"The Daily Biotech Pulse: AEterna Zentaris Explores Options, Verastem Plunges On Weak Copiktra Sales, FDA Nod For Aerie",2019-03-13 07:27:00-04:00,AEZS,negative
38265.0,Aeterna Zentaris Shares To Resume Trade At 5:00 p.m. EDT,2019-03-12 16:45:00-04:00,AEZS,positive
38266.0,Aeterna Zentaris Announces Strategic Review And Engagement Of Financial Advisor; Alternatives Include A Sale Of The Company And Opportunities For The License Of Macimorelin Outside Of The United States And Canada,2019-03-12 16:34:00-04:00,AEZS,positive
38267.0,"AEterna Zentaris Shares Halted, News Pending",2019-03-12 15:18:00-04:00,AEZS,positive
38268.0,"The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results",2019-02-05 07:47:00-05:00,AEZS,positive
38269.0,58 Biggest Movers From Yesterday,2019-01-17 05:27:00-05:00,AEZS,neutral
38270.0,Aeterna Zentaris Reports Received European Marketing Clearance For Macimorelin,2019-01-16 09:06:00-05:00,AEZS,neutral
38271.0,'$AEZS Aeterna Zentaris receives European Commission Approval for Macimorelin for diagnosis of adult growth hormone deficiency.' -Tweet From TradeHawk,2019-01-11 10:09:00-05:00,AEZS,positive
38272.0,"Aeterna Zentaris Settles Dispute With David, Dodd, Philip Theodore, Co. To Pay Dodd $775K",2018-12-21 17:07:00-05:00,AEZS,negative
38273.0,"Stocks Which Set New 52-Week High Yesterday, Mon., Dec. 3, 2018",2018-12-04 09:20:00-05:00,AEZS,neutral
38274.0,"The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO",2018-12-04 07:59:00-05:00,AEZS,neutral
38275.0,56 Biggest Movers From Yesterday,2018-12-04 05:02:00-05:00,AEZS,neutral
38276.0,Aeterna Zentaris Receives Positive European Medicines Agency Opinion Of Macimorelin For Diagnosis of Adult Growth Hormone Deficiency,2018-11-19 08:05:00-05:00,AEZS,positive
38277.0,55 Biggest Movers From Friday,2018-11-19 05:53:00-05:00,AEZS,neutral
38278.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Fri., Nov. 16, 2018",2018-11-16 11:18:00-05:00,AEZS,positive
38279.0,"AEterna Zentaris Late Tuesday Reported Q3 EPS $(0.15) Up From $(0.61) YoY, Sales $663K Up From $241K YoY",2018-11-07 09:29:00-05:00,AEZS,neutral
38280.0,"Aeterna Zentaris Settles Dispute With Cogas Consulting, Co. Agrees To Pay $625K; Contractual Relationship Between Companies Is Now Terminated",2018-11-06 08:33:00-05:00,AEZS,negative
38281.0,56 Stocks Moving In Thursday's Mid-Day Session,2018-11-01 12:59:00-04:00,AEZS,neutral
38282.0,"Aeterna Zentaris Announces Novo Nordisk Acquires Rights to Macrilen in the United States and Canada, Terms Not Disclosed",2018-11-01 09:06:00-04:00,AEZS,positive
38283.0,35 Stocks Moving In Thursday's Pre-Market Session,2018-11-01 08:04:00-04:00,AEZS,neutral
38284.0,Why AEterna Zentaris Shares Surged On Novo Nordisk-Strongbridge Biopharma Deal,2018-10-31 16:13:00-04:00,AEZS,positive
38285.0,AEterna Zentaris shares are up 63.9% following a deal between Novo Nordisk and Stonebridge for the rights to MACRILEN; AEterna Zentaris will receive 15%-18% royalties from the sale of MACRILEN rights.,2018-10-31 15:20:00-04:00,AEZS,positive
38286.0,"Aeterna Zentaris Shares Up 25% Following Deal Between Novo Nordisk, Strongbridge For Rights To MACRILEN; Aeterna Zentaris Receives 15-18% Royalties From Sales Of MACRILEN In US, Canada",2018-10-31 09:36:00-04:00,AEZS,positive
38287.0,Aeterna Zentaris Appoints Leslie Auld As Chief Financial Officer,2018-09-25 08:01:00-04:00,AEZS,neutral
38288.0,"AEterna Zentaris Q2 EPS $(0.16) Beats $(0.32) Estimate, Sales $168K Miss $2M Estimate",2018-08-09 16:41:00-04:00,AEZS,negative
38289.0,30 Stocks Moving In Thursday's Pre-Market Session,2018-06-21 08:03:00-04:00,AEZS,neutral
38290.0,Maxim Group Terminates AEterna Zentaris,2018-06-15 16:30:00-04:00,AEZS,neutral
38291.0,58 Biggest Movers From Yesterday,2018-06-01 04:47:00-04:00,AEZS,neutral
38292.0,42 Biggest Movers From Yesterday,2018-05-30 05:30:00-04:00,AEZS,neutral
38293.0,37 Stocks Moving In Tuesday's Mid-Day Session,2018-05-29 12:44:00-04:00,AEZS,neutral
38294.0,28 Stocks Moving In Tuesday's Pre-Market Session,2018-05-08 08:03:00-04:00,AEZS,neutral
38295.0,"Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure",2018-05-08 07:55:00-04:00,AEZS,neutral
38296.0,Aeterna Zentaris Shares Up 9.0% After Hours Following Q1 Beat,2018-05-07 17:44:00-04:00,AEZS,positive
38297.0,"AEterna Zentaris Q1 EPS $0.88 Beats $(0.31) Estimate, Sales $24.6M Beat $130K Estimate",2018-05-07 16:16:00-04:00,AEZS,neutral
38298.0,"Aeterna Zentaris Q4 EPS $(0.03) vs $(0.71) In Same Qtr. Last Year, Sales $100K Misses $130K Est.",2018-03-28 07:06:00-04:00,AEZS,negative
38299.0,"Earnings Scheduled For March 27, 2018",2018-03-27 05:27:00-04:00,AEZS,neutral
38300.0,Advaxis Shares Down 16.3% After Co. Announced Monday a Clinical Hold In Axalimogene Filolisbac Phase 1/2 Combination Study With AstraZeneca's IMFINZI,2018-03-13 13:51:00-04:00,AEZS,positive
38301.0,Aeterna Zentaris Names James Clavijo CFO,2018-03-05 16:13:00-05:00,AEZS,neutral
38302.0,"Aeterna Zentaris Comments on the Class Actin Lawsuit Related to Macrilen, Says Cannot Predict Expenses so Not Adding a Liability",2018-03-05 07:47:00-05:00,AEZS,neutral
38303.0,44 Biggest Movers From Yesterday,2018-01-18 04:43:00-05:00,AEZS,neutral
38304.0,Mid-Afternoon Market Update: NeuroMetrix Climbs Following Announcement Of Collaboration With GlaxoSmithKline; Aerohive Networks Shares Drop,2018-01-17 14:31:00-05:00,AEZS,neutral
38305.0,38 Stocks Moving In Wednesday's Mid-Day Session,2018-01-17 12:28:00-05:00,AEZS,neutral
38306.0,Mid-Day Market Update: Dow Surges Over 150 Points; HTG Molecular Diagnostics Shares Plunge,2018-01-17 12:18:00-05:00,AEZS,positive
38307.0,Aeterna Zentaris Shares Up 19.32% After News Of Licensing Deal With Stonebridge Pharma,2018-01-17 11:47:00-05:00,AEZS,positive
38308.0,Mid-Morning Market Update: Markets Open Higher; Goldman Sachs Beats Q4 Expectations,2018-01-17 10:09:00-05:00,AEZS,neutral
38309.0,30 Stocks Moving In Wednesday's Pre-Market Session,2018-01-17 08:01:00-05:00,AEZS,neutral
38310.0,"Aeterna Zentaris Shares Resume, Stock Up 49%",2018-01-17 07:30:00-05:00,AEZS,positive
38311.0,Aeterna Zentaris Shares To Resume Trade At 7:30 a.m. EST,2018-01-17 07:18:00-05:00,AEZS,positive
38312.0,UPDATE: Aeterna Zentaris Says Will Receive 1-Time Milestone Payment Of $5M From Stonebridge For FDA Approval Of Pediatric Indication For Macrilen,2018-01-17 07:05:00-05:00,AEZS,positive
38313.0,UPDATE: Aeterna Zentaris Will Receive Scheduled Of 1-Time Payments From Stonebridge Following Achievement Of 5 Commercial Milestone Events,2018-01-17 07:04:00-05:00,AEZS,neutral
38314.0,"UPDATE: Aeterna Zentaris Says Following End Of Patent Protection For Macrilen, Co. Will Be Entitled To 5% Royalty On Net Sales",2018-01-17 07:03:00-05:00,AEZS,positive
38315.0,"UPDATE: Aeterna Zentaris Will Receive Upfront Payment Of $24M From Stonebridge; As Long As Macrilen Is Patent Protected, Co. Will Be Entitled To 15% Royalty On Net Sales Up To $75M, 18% Above $75M",2018-01-17 07:03:00-05:00,AEZS,positive
38316.0,"UPDATE: Zeterna Zentaris, Stonebridge Pharma Will Carry Out Development, Manufacturing, Registration, Commercialization Of Macrilen In US, Canada",2018-01-17 07:02:00-05:00,AEZS,neutral
38317.0,"Aeterna Zentaris Reports Entered Into Licensing Deal With Strongbridge For Macrilen In US, Canada",2018-01-17 07:01:00-05:00,AEZS,neutral
38318.0,Aeterna Zentaris Shares Halted News Pending,2018-01-17 06:55:00-05:00,AEZS,positive
38319.0,44 Biggest Movers From Friday,2017-12-26 05:09:00-05:00,AEZS,neutral
38320.0,"Aeterna Zentaris Offers Update On Litigation Against David Dodd, Philip Theodore: Counterclaim Alleges Defamatory Statements Related To Dodd, Theodore Were Made In Co. Press Release, Claims Damages Of $6M",2017-12-22 16:16:00-05:00,AEZS,negative
38321.0,36 Stocks Moving In Friday's Mid-Day Session,2017-12-22 12:33:00-05:00,AEZS,neutral
38322.0,Mid-Day Market Update: Ignyta Surges Following Merger Deal With Roche; Agile Therapeutics Shares Plunge,2017-12-22 12:16:00-05:00,AEZS,positive
38323.0,38 Biggest Movers From Yesterday,2017-12-22 05:50:00-05:00,AEZS,neutral
38324.0,Mid-Afternoon Market Update: Aeterna Zentaris Climbs Following FDA Approval Of Macrilen; Apogee Shares Slide,2017-12-21 14:39:00-05:00,AEZS,positive
38325.0,36 Stocks Moving In Thursday's Mid-Day Session,2017-12-21 12:17:00-05:00,AEZS,neutral
38326.0,Mid-Day Market Update: Dow Surges Over 100 Points; PG&E Shares Plunge,2017-12-21 12:07:00-05:00,AEZS,positive
38327.0,Mid-Morning Market Update: Markets Open Higher; Conagra Tops Q2 Expectations,2017-12-21 10:13:00-05:00,AEZS,positive
38328.0,35 Stocks Moving In Thursday's Pre-Market Session,2017-12-21 08:00:00-05:00,AEZS,neutral
38329.0,A Peek Into The Markets: U.S. Stock Futures Up Ahead Of Economic Data,2017-12-21 06:50:00-05:00,AEZS,neutral
38330.0,"10 Stocks To Watch For December 21, 2017",2017-12-21 05:32:00-05:00,AEZS,neutral
38331.0,Aeterna Zentaris Shares Rise 74% to $3.50 Following Wednesday Announcement FDA Approval of Macrilen for Diagnosis of Adult Growth Hormone Deficiency,2017-12-21 04:51:00-05:00,AEZS,positive
38332.0,"Aeterna Zentaris Shares Resume, Spike Higher, Now Up 48.6%",2017-12-20 17:30:00-05:00,AEZS,positive
38333.0,Aeterna Zentaris Shares To Resume Trade At 5:30 p.m. EST,2017-12-20 17:15:00-05:00,AEZS,positive
38334.0,Aeterna Zentaris Reports FDA Approval Of Macrilen For Diagnosis Of Adult Growth Hormone Deficiency,2017-12-20 17:01:00-05:00,AEZS,positive
38335.0,Aeterna Zentaris Shares Halted News Pending,2017-12-20 15:57:00-05:00,AEZS,positive
38336.0,Aeterna Zentaris Reports Departure of Interim CFO Jeffrey Whitnell Effective Immediately,2017-12-08 08:00:00-05:00,AEZS,positive
38337.0,Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates,2017-11-30 08:34:00-05:00,AEZS,neutral
38338.0,Aeterna Zentaris Shares Up 1.5% Just After Open Following News Mon. Afternoon The Co.'s Macrilen Hormone Treatment Was Accepted For Marketing By the EMA,2017-11-28 09:33:00-05:00,AEZS,positive
38339.0,Aeterna Zentaris Announces EMA Has Accepted Marketing Authorization Application For Macrilen,2017-11-27 16:42:00-05:00,AEZS,positive
38340.0,"Aeterna Zentaris Reports Q3 EPS $(0.61) vs $(0.26) Est., Sales $241k vs $120K Est.",2017-11-08 17:50:00-05:00,AEZS,neutral
38341.0,Aeterna Zentaris Names Jeffrey Whitnell Interim CFO,2017-09-25 16:30:00-04:00,AEZS,neutral
38342.0,"Aeterna Zentaris Announces Departure of Vice President, Finance & Chief Accounting Officer Geneviéve Lemaire",2017-09-01 16:32:00-04:00,AEZS,neutral
38343.0,"Aeterna Zentaris Shares Resume Trade, Now Up 6% Following News Co. Has Engaged Advisors",2017-08-08 17:11:00-04:00,AEZS,positive
38344.0,"Aeterna Zentaris Commences Legal Action Against David Dodd and Philip Theodore, Aeterna Alleges That Former CEO Dodd And Former General Counsel Theodore Breached Fiduciary Duties Owed To Company; Developed Secret Plants To Acquire U.S. Rights To Macrilen",2017-08-03 13:27:00-04:00,AEZS,positive
38345.0,"Wall Street's M&A Chatter From July 25: Aeterna Zentaris, Rent-A-Center, Michael Kors-Jimmy Choo",2017-07-26 07:07:00-04:00,AEZS,neutral
38346.0,AeternaZentaris Shares Spike ~$0.10 Over Last Min. As Traders Circulate NY Post Article 'Longtime hockey exec rebrands himself as activist investor'; BZ NOTE: La Presse Article Earlier (7 a.m. EDT) Highlighted Same Story,2017-07-25 11:09:00-04:00,AEZS,positive
38347.0,25 Stocks Moving In Tuesday's Pre-Market Session,2017-07-25 08:24:00-04:00,AEZS,neutral
38348.0,12 Biggest Mid-Day Losers For Monday,2017-07-24 12:49:00-04:00,AEZS,negative
38349.0,22 Stocks Moving In Friday's Pre-Market Session,2017-07-21 08:12:00-04:00,AEZS,neutral
38350.0,Aeterna Zentaris +17% Premarket @$3.28,2017-07-21 04:33:00-04:00,AEZS,neutral
38351.0,"Aeterna Zentaris Names Michael Ward CEO, David Dodd 'Ceased To Be' CEO With Immediate Effect; Co. Also Announces Formation Of Special 'Strategic Review Committee'",2017-07-20 17:02:00-04:00,AEZS,positive
38352.0,Mid-Afternoon Market Update: MarineMax Drops Following Q3 Results; Sarepta Shares Spike Higher,2017-07-20 14:31:00-04:00,AEZS,positive
38353.0,15 Biggest Mid-Day Gainers For Thursday,2017-07-20 12:25:00-04:00,AEZS,neutral
38354.0,Aeterna Zentaris Spikes to High of $3.25,2017-07-20 11:31:00-04:00,AEZS,neutral
38355.0,28 Stocks Moving In Thursday's Pre-Market Session,2017-07-20 08:10:00-04:00,AEZS,neutral
38356.0,Mid-Afternoon Market Update: Scripps Rises On Report Of Merger Talks With Discovery; DryShips Shares Slide,2017-07-19 14:30:00-04:00,AEZS,positive
38357.0,"Aeterna Zentaris Inc. Up 124% On Day, Hearing Maxim Raised Price Target On Co. From $2 To $4",2017-07-19 12:44:00-04:00,AEZS,neutral
38358.0,18 Biggest Mid-Day Gainers For Wednesday,2017-07-19 12:22:00-04:00,AEZS,neutral
38359.0,Mid-Day Market Update: Crude Oil Up Over 1%; Cyclacel Pharma Shares Plummet,2017-07-19 12:04:00-04:00,AEZS,negative
38360.0,Mid-Morning Market Update: Markets Rise; Morgan Stanley Beats Q2 Estimates,2017-07-19 10:08:00-04:00,AEZS,neutral
38361.0,25 Stocks Moving In Wednesday's Pre-Market Session,2017-07-19 08:09:00-04:00,AEZS,neutral
38362.0,"Aeterna Zentaris Reports NDA For Macrilen For Evaluation Of Growth Hormone Deficiency In Adults Granted Dec. 30, 2017 PDUFA Date",2017-07-18 17:01:00-04:00,AEZS,positive
38363.0,Aeterna Zentaris Reports Resubmission Of NDA For Macrilen,2017-06-30 09:16:00-04:00,AEZS,neutral
38366.0,"Marcum Conference To Connect Public, Private Micro-Caps With Critical Investors",2017-05-18 07:40:00-04:00,AEZS,negative
38367.0,"Aeterna Zentaris Reports Q1 EPS $(0.31) vs $(0.30) Est., Sales $261K vs $900K Est.",2017-05-08 16:40:00-04:00,AEZS,neutral
38368.0,Mid-Afternoon Market Update: NASDAQ Up 50 Points; Ocwen Financial Shares Spike Higher,2017-05-01 14:31:00-04:00,AEZS,positive
38369.0,15 Biggest Mid-Day Losers For Monday,2017-05-01 13:05:00-04:00,AEZS,negative
38370.0,Mid-Day Market Update: Crude Oil Down 1.5%; Neurotrope Shares Plummet,2017-05-01 12:11:00-04:00,AEZS,negative
38371.0,Mid-Morning Market Update: Markets Mostly Higher; DISH Network Profit Tops Estimates,2017-05-01 10:10:00-04:00,AEZS,positive
38372.0,"Adam Feuerstein Tweets: $AEZS — Zoptrex mOS 10.9 months vs doxorubicin mOS 10.8 months. 

This is what happens when you compare doxorubucin to doxorubicin. Duh.",2017-05-01 08:17:00-04:00,AEZS,neutral
38373.0,Aeterna Zentaris Shares to Resume Trade at 8:30 a.m. EDT,2017-05-01 08:14:00-04:00,AEZS,positive
38374.0,Aeterna Zentaris Phase 3 Zoptec Study Did Not Achieve Primary Endpoint,2017-05-01 08:02:00-04:00,AEZS,neutral
38375.0,"Aeterna Zentaris Shares Halted News Pending, Ahead of Data",2017-05-01 07:58:00-04:00,AEZS,positive
38376.0,Aeterna Zentaris Will Announce Top-Line Results Of ZoptEC Phase 3 Study May 1 Before Market Open,2017-04-28 17:03:00-04:00,AEZS,neutral
38377.0,Aeterna Zentaris Announces Replacement at the Market Issuance Program with H.C. Wainwright,2017-04-28 04:32:00-04:00,AEZS,neutral
38378.0,Adam Feuerstein Tweets: I'm told $AEZS moved the goal line. Very well…,2017-04-27 12:41:00-04:00,AEZS,neutral
38379.0,"Adam Feuerstein Tweets: I forgot about $AEZS. Zoptrex ph3 results expected end of April, so by tomorrow. Another doxorubicin reformulation a la $CYTR. Uh oh…",2017-04-27 12:25:00-04:00,AEZS,neutral
38380.0,15 Biggest Mid-Day Gainers For Thursday,2017-03-30 12:39:00-04:00,AEZS,neutral
38381.0,20 Stocks Moving In Thursday's Pre-Market Session,2017-03-30 08:21:00-04:00,AEZS,neutral
38382.0,Aeterna Zentaris Intends to File NDA with Respect to Macrilen In Q3,2017-03-30 08:00:00-04:00,AEZS,positive
38383.0,"Aeterna Zentaris Reports ATM Issuance Program for $9M in Shares, Can Sell Up to 3M Shares",2017-03-28 17:00:00-04:00,AEZS,positive
38384.0,F-3 from Aeterna Zentaris Shows Registration for $50M Common Stock Offering,2017-03-21 16:36:00-04:00,AEZS,neutral
38385.0,"Aeterna Zentaris Reports EMA Pediatric Committee Agreement on the Pediatric Investigation Plan for Macrilen, Agrees That Co. May Defer Conducting Pediatric Investigation Plan Until After It Files A Marketing Authorization Application",2017-03-07 08:31:00-05:00,AEZS,positive
38386.0,25 Stocks Moving In Wednesday's Pre-Market Session,2017-02-15 08:39:00-05:00,AEZS,neutral
38387.0,Aeterna Zentaris Reports Plans to Pursue FDA Registration of Macrilen,2017-02-13 07:30:00-05:00,AEZS,neutral
38388.0,15 Biggest Mid-Day Gainers For Tuesday,2017-01-31 12:20:00-05:00,AEZS,neutral
38389.0,Mid-Day Market Update: Dow Falls Over 100 Points; DryShips Shares Spike Higher,2017-01-31 12:08:00-05:00,AEZS,positive
38390.0,Mid-Morning Market Update: Markets Open Lower; Mastercard Earnings Beat Views,2017-01-31 09:53:00-05:00,AEZS,negative
38391.0,22 Stocks Moving In Tuesday's Pre-Market Session,2017-01-31 08:22:00-05:00,AEZS,neutral
38392.0,18 Stocks Moving In Wednesday's Pre-Market Session,2017-01-18 08:25:00-05:00,AEZS,neutral
38393.0,Mid-Afternoon Market Update: CEB Surges On Acquisition News; Macy's Shares Slide,2017-01-05 14:35:00-05:00,AEZS,positive
38394.0,18 Biggest Mid-Day Losers For Thursday,2017-01-05 13:03:00-05:00,AEZS,negative
38395.0,Mid-Day Market Update: Dow Falls Over 100 Points; Kohl's Shares Plummet,2017-01-05 12:00:00-05:00,AEZS,positive
38396.0,Mid-Morning Market Update: Markets Mixed; Walgreens Sales Miss Estimates,2017-01-05 10:05:00-05:00,AEZS,negative
38397.0,25 Stocks Moving In Thursday's Pre-Market Session,2017-01-05 08:23:00-05:00,AEZS,neutral
38398.0,Aeterna Zentaris Shares Down 47.95% After Resuming Trade At 5:46pm,2017-01-04 17:54:00-05:00,AEZS,positive
38399.0,"Aeterna Zentaris Macrilen Failed To Achieve Its Objective In Phase 3 Trial, Company Evaluating Whether It Will Continue Development",2017-01-04 17:16:00-05:00,AEZS,negative
38400.0,Aeterna Zentaris Offers Results of Confirmatory Phase 3 Trial of Macrilen,2017-01-04 17:15:00-05:00,AEZS,neutral
38401.0,Aeterna Zentaris Shares Halted News Pending,2017-01-04 17:15:00-05:00,AEZS,positive
38402.0,"Aeterna Zentaris Reports Q3 EPS $(0.61) vs. Est. $(0.73), Rev. $269K vs. Est. $160K",2016-11-08 16:49:00-05:00,AEZS,neutral
38403.0,18 Stocks Moving In Friday's Pre-Market Session,2016-10-14 08:37:00-04:00,AEZS,neutral
38404.0,10 Biggest Mid-Day Gainers For Thursday,2016-10-13 12:29:00-04:00,AEZS,neutral
38405.0,"Aeterna Zentaris Reports Exclusive License Deal with Specialised Therapeutics Asia for Potential Marketing of Zoptrex in Australia, New Zealand",2016-10-12 08:00:00-04:00,AEZS,positive
38406.0,"Aeterna Zentaris Reports Q2 EPS $(0.71) vs $(0.82) Est., Sales $96K vs $750K Est.",2016-08-09 16:45:00-04:00,AEZS,neutral
38407.0,Aeterna Zentaris and Rafa Laboratories Sign Exclusive License Agreement for Zoptrex in Israel,2016-08-01 08:34:00-04:00,AEZS,positive
38408.0,Mid-Afternoon Market Update: IntriCon Drops On Weak Forecast; Thor Industries Shares Spike Higher,2016-07-01 14:32:00-04:00,AEZS,negative
38409.0,12 Biggest Mid-Day Gainers For Friday,2016-07-01 12:36:00-04:00,AEZS,neutral
38410.0,Mid-Day Market Update: Franklin Covey Slides Following Weak Results; Aeterna Zentaris Shares Surge,2016-07-01 12:12:00-04:00,AEZS,negative
38411.0,Mid-Morning Market Update: Markets Open Higher; Micron To Lower Jobs,2016-07-01 10:11:00-04:00,AEZS,negative
38412.0,"Aeterna Zentaris, Orient EuroPharma Co., Ltd. Sign Exclusive License Agreement for Zoptrex in Taiwan and Southeast Asia",2016-07-01 08:30:00-04:00,AEZS,positive
38413.0,Aeterna Zentaris Announces Submission Of Investigational New Drug Application,2016-06-14 17:01:00-04:00,AEZS,neutral
38414.0,Aeterna Zentaris Says Pivotal Phase III Trial for Endometrial Cancer Expected to be Closed in Q3'16,2016-06-06 17:00:00-04:00,AEZS,negative
38415.0,Aeterna Zentaris Reports Q1 EPS $(0.37) May Not Compare to $(0.74) Est.,2016-05-09 17:05:00-04:00,AEZS,neutral
38416.0,Aeterna Zentaris Acquires Exclusive U.S. Promotional Rights for APIFINY Prostate Cancer Blood Test,2016-04-27 16:10:00-04:00,AEZS,negative
38417.0,Aeterna Zentaris Reports Q4 EPS $(1.46) vs. Est. $(1.30),2016-03-29 17:01:00-04:00,AEZS,neutral
38418.0,Aeterna Zentaris Reports Development Progress of Zoptrex in China: Clinical Development Expected to Start in '16,2016-03-01 08:32:00-05:00,AEZS,positive
38419.0,Aeterna Zentaris Starts Promotional Activities for APIFINY Prostate Cancer Blood Test,2016-02-23 08:30:00-05:00,AEZS,negative
38420.0,Aeterna Zentaris Names Genevieve Lemaire Chief Accounting Officer,2016-02-18 16:27:00-05:00,AEZS,neutral
38421.0,AEterna Zentraris Surged 17%: Here Is What You Need To Know,2016-01-25 13:27:00-05:00,AEZS,neutral
38422.0,"Aeterna Zentaris Spike to High of $3.60, +17.5%; Co Announced Stock Purchases by Management",2016-01-25 13:22:00-05:00,AEZS,neutral
38423.0,Aeterna Zentaris PR Highlights Recent Management Stock Purchases,2016-01-25 08:30:00-05:00,AEZS,neutral
38424.0,Mid-Morning Market Update: Markets Open Higher; Bank of America Earnings Top Views,2016-01-19 10:05:00-05:00,AEZS,positive
38425.0,Aeterna Zentaris +24.34% Premarket @$3.32; Co Concludes Successful Meeting of Clinical Investigators for Confirmatory Phase 3 Trial of Macrilen,2016-01-19 08:45:00-05:00,AEZS,positive
38426.0,Aeterna Zentaris Finishes Meeting With Clinical Investigators For Phase 3 Trial Of Macrilen,2016-01-19 08:30:00-05:00,AEZS,neutral
38427.0,UPDATE: Aeterna Zentaris Says in Early Stages of Developing Compounds Based on Another Cytotoxic Agent Which Would Follow Zoptrex,2016-01-13 15:09:00-05:00,AEZS,neutral
38428.0,UPDATE: Aeterna Zentaris Syas Offered Update on Progress of Zoptrex: Recently Received DSMB Recommendation to Continue ZoptEC Phase 3 Trial,2016-01-13 15:09:00-05:00,AEZS,positive
38429.0,Aeterna Zentaris Release Shows Affirmation of Focus on Targeted Oncology at JP Morgan Healthcare Conference,2016-01-13 15:08:00-05:00,AEZS,positive
38430.0,UPDATE: Aeterna Zentaris Prospectus Allows for Co. to Offer Up to $150M in Mixed Securities,2015-12-30 16:06:00-05:00,AEZS,positive
38431.0,Aeterna Zentaris Reports Filing of Prelim. Base Shelf Prospectus,2015-12-30 16:06:00-05:00,AEZS,neutral
38432.0,13G Filing from Sabby Mgmt on Aeterna Zentaris Shows New 7.05% Stake,2015-12-17 13:04:00-05:00,AEZS,neutral
38433.0,Benzinga's Top #PreMarket Losers,2015-12-09 08:28:00-05:00,AEZS,negative
38434.0,"Aeterna Zentaris Prices Offering of Common Shares, Warrants at $5.55/Share Plus Warrant to Purchase 0.7 Common Shares",2015-12-09 08:26:00-05:00,AEZS,positive
38435.0,"Aeterna Zentaris Reports Proposed Offering Of Stock, Warrants; Details Not Disclosed",2015-12-08 16:19:00-05:00,AEZS,neutral
38436.0,"Aeterna Zentaris Regains NASDAQ $1/Share Minimum Compliance, Reports FY16 Corp. Objectives",2015-12-08 08:33:00-05:00,AEZS,neutral
38437.0,"HC Wainwright Reiterates Buy, Raises Target from $11 to $12 on Aeterna Zentaris, Highlights 'Building an Oncology Franchise Ahead of Zoptrex'",2015-12-02 07:08:00-05:00,AEZS,neutral
38438.0,Benzinga's Volume Movers,2015-12-01 10:25:00-05:00,AEZS,neutral
38439.0,"Aeterna Zentaris, Armune BioScience Finish Co-Marketing Agreement for APIFINY Prostate Cancer Blood Test",2015-12-01 08:30:00-05:00,AEZS,negative
38440.0,Morning Market Losers,2015-11-30 09:51:00-05:00,AEZS,negative
38441.0,Benzinga's Top #PreMarket Losers,2015-11-30 08:25:00-05:00,AEZS,negative
38442.0,"UPDATE: Shkreli Says Aeterna Zentaris, Cyclacel, Macrocure Worthless",2015-11-30 06:43:00-05:00,AEZS,negative
38443.0,Aeterna Zentaris Spikes Higher,2015-11-27 10:15:00-05:00,AEZS,neutral
38444.0,Morning Market Losers,2015-11-27 09:50:00-05:00,AEZS,negative
38445.0,Benzinga's Top #PreMarket Gainers,2015-11-27 08:08:00-05:00,AEZS,positive
38446.0,Aeterna Zentaris +9% Premarket @$12.43,2015-11-27 06:43:00-05:00,AEZS,neutral
38447.0,"UPDATE: Aeterna Zentaris Affirms Business, Prospects Remain Fundamentally Strong",2015-11-25 13:02:00-05:00,AEZS,positive
38448.0,Aeterna Zentaris Affirms Fundamental Strength Of Business,2015-11-25 13:00:00-05:00,AEZS,positive
38449.0,Aeterna Zentaris Shares Selling Following PR Confirming No Corporate Developments,2015-11-24 11:42:00-05:00,AEZS,neutral
38450.0,Aeterna Zentaris PR Confirms No Corporate Developments,2015-11-24 11:30:00-05:00,AEZS,negative
38451.0,Benzinga's Volume Movers,2015-11-24 11:06:00-05:00,AEZS,neutral
38452.0,Morning Market Gainers,2015-11-24 09:56:00-05:00,AEZS,neutral
38453.0,Benzinga's Top #PreMarket Gainers,2015-11-24 08:15:00-05:00,AEZS,positive
38454.0,Aeterna Zentaris +45% Premarket @$12.35,2015-11-24 06:32:00-05:00,AEZS,neutral
38455.0,Aeterna Zentaris Senior VP Phil Theodore Tells Benzinga There is No News That Can be Discussed With Analyst or Media; Says Stay Tuned for Public Information,2015-11-23 16:50:00-05:00,AEZS,negative
38456.0,Aeterna Zentaris +30% After-Hours @$9.80,2015-11-23 16:23:00-05:00,AEZS,neutral
38457.0,Aeterna Zentaris +91% @$8.09,2015-11-23 15:03:00-05:00,AEZS,neutral
38458.0,Aeterna Zentaris Reports First Patient Enrolled for Confirmatory Phase 3 Trial of Macrilen for AGHD,2015-11-19 08:31:00-05:00,AEZS,neutral
38459.0,Aeterna Zentaris Offers Details of Steps to Regain NASDAQ Compliance,2015-11-18 08:35:00-05:00,AEZS,neutral
38460.0,Aeterna Zentaris Reports Q3 $(0.07) vs. Est. $(0.06),2015-11-05 17:05:00-05:00,AEZS,neutral
38461.0,Aeterna Zentaris Shares Fall Quickly,2015-11-03 11:22:00-05:00,AEZS,positive
38462.0,Aeterna Zentaris Reports Agreement to Exercise Substantially All Remaining Series B Warrants,2015-11-02 09:32:00-05:00,AEZS,positive
38463.0,Leading Independent Advisory Firms ISS and Glass Lewis Recommend Shareholders of Aeterna Zentaris Vote FOR Share Consolidation,2015-10-27 08:33:00-04:00,AEZS,positive
38464.0,Aeterna Zentaris Reports Special Meeting of Shareholders and Mailing of Management Information Circular,2015-10-16 07:32:00-04:00,AEZS,positive
38465.0,Aeterna Zentaris: Data and Safety Monitoring Board Recommends Continuation of ZoptEC Phase 3 Trial in Advanced Endometrial Cancer,2015-10-13 07:35:00-04:00,AEZS,positive
38466.0,"Aeterna Zentaris' Zoptarelin Doxorubicin Meets Phase 2 Primary Endpoint in Men with Heavily Pretreated Castration, Taxane Resistant Prostate Cancer",2015-09-28 11:00:00-04:00,AEZS,negative
38467.0,Aeterna Zentaris Fall 25% Premarket Following Announcement of Amendment to Series B Warrants,2015-09-21 09:09:00-04:00,AEZS,neutral
38468.0,"Aeterna Zentaris Announces Amendment to Series B Warrants, Enters Definitive Agreement With ~90% Of Outstanding Series B Holders",2015-09-21 09:04:00-04:00,AEZS,positive
38469.0,Stocks Hitting 52-Week Lows,2015-09-08 10:15:00-04:00,AEZS,negative
38470.0,Aeterna Zentaris Reports Q2 EPS $(0.14) vs. Est. $(0.08),2015-08-13 16:19:00-04:00,AEZS,neutral
38471.0,"Aeterna Zentaris Reports Data, Safety Monitoring Board Scheduled to Close Second Interim Analysis of ZoptEC Phase 3 Trial in Early October",2015-08-11 07:33:00-04:00,AEZS,positive
38472.0,"Aeterna Zentaris Reports Data, Safety Monitoring Board Scheduled to Complete Second Interim Analysis of the ZoptEC Phase 3 Trial in Endometrial Cancer in Early October",2015-08-11 07:30:00-04:00,AEZS,negative
38473.0,"Aeterna Zentaris Grants Option to Develop, Commercialize Oral Allogenic Cancer Vaccine Technology",2015-07-28 07:33:00-04:00,AEZS,negative
38474.0,Aeterna Zentaris Begins Promotional Activities for EMD Serono's Saizen [Somatropin  for Injection],2015-07-27 07:31:00-04:00,AEZS,neutral
38475.0,Aeterna Zentaris Finishes Patient Recruitment for ZoptEC Phase 3 Study with Zoptarelin Doxorubicin in Advanced Endometrial Cancer,2015-06-30 07:31:00-04:00,AEZS,negative
38476.0,Aeterna Zentaris Announces Selection of Ergomed to Conduct Confirmatory Phase 3 Clinical Trial of Macrilen in AGHD,2015-06-25 07:31:00-04:00,AEZS,neutral
38477.0,Aeterna Zentaris Reports Extension to Regain NASDAQ Compliance for Minimum Bid Price Rule,2015-06-18 07:31:00-04:00,AEZS,neutral
38478.0,Aeterna Zentaris' Confirmatory Phase 3 Study for Macrilen in AGHD Meets EMA's Study-Design Expectations,2015-05-26 07:30:00-04:00,AEZS,neutral
38479.0,"HC Wainwright Upgrades AEterna Zentaris to Buy, Announces $1.25 PT",2015-04-14 07:09:00-04:00,AEZS,neutral
38480.0,Aeterna Zentaris Reports Plans to Start Phase 3 Study of Macrilen™ in AGHD After Successful Meeting with FDA,2015-04-13 07:31:00-04:00,AEZS,positive
38481.0,Aeterna Zentaris Transfers Agreement of its Discovery Library with the Medical University of South Carolina,2015-03-31 07:31:00-04:00,AEZS,positive
38482.0,"Earnings Scheduled For March 17, 2015",2015-03-17 05:03:00-04:00,AEZS,neutral
38483.0,Aeterna Zentaris: Final Data for Phase 1 Portion of Ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin in Prostate Cancer Published in Clinical Cancer Research,2014-12-29 07:31:00-05:00,AEZS,negative
38484.0,Aeterna Zentaris Announces Receiving Notification from NASDAQ Related to Minimum Bid Price,2014-12-19 09:00:00-05:00,AEZS,neutral
38485.0,"Aeterna Zentaris, Sinopharm A-Think Report Signing of Master Collaboration Deal for Zoptarelin Doxorubicin in China",2014-12-01 07:33:00-05:00,AEZS,neutral
38486.0,Aeterna Zentaris Adds Hollings Cancer Center To Multi-National Phase 3 Trial In Endometrial Cancer,2014-11-20 07:32:00-05:00,AEZS,negative
38487.0,Morning Market Losers ,2014-11-06 09:56:00-05:00,AEZS,negative
38488.0,PREVIEW: Aeterna Zentaris to Resume Trading at 7:30 AM ET,2014-11-06 07:12:00-05:00,AEZS,neutral
38489.0,Aeterna Zentaris Inc Announces It Has Received Complete Response Letter From FDA For Macrilen ,2014-11-06 07:08:00-05:00,AEZS,neutral
38490.0,UPDATE: Aeterna Zentaris Halt Likely Related to PDUFA Date for Macrilen,2014-11-05 15:47:00-05:00,AEZS,neutral
38491.0,Shares of Aeterna Zentaris Halted News Pending,2014-11-05 15:44:00-05:00,AEZS,positive
38492.0,AEterna Zentaris Inc. Reports Q3 EPS of $(0.20) vs $(0.16) Est,2014-11-04 16:32:00-05:00,AEZS,neutral
38493.0,"AEterna Zentaris Inc. Reports Q2 EPS of $(0.09) vs $(0.19) Est; Revenue of $0.00, Down 100% YOY",2014-08-07 16:34:00-04:00,AEZS,neutral
38494.0,UPDATE: H.C. Wainwright Initiates Coverage On AEterna Zentaris,2014-07-17 08:51:00-04:00,AEZS,neutral
38495.0,"HC Wainwright Initiates Coverage on AEterna Zentaris Inc. at Buy, Announces $3.00 PT",2014-07-17 07:45:00-04:00,AEZS,neutral
38496.0,"UPDATES: Aeterna Zentaris Names David Dodd as Chair, Says May Sell Up to 14M Shares for Up to $15M",2014-05-12 07:35:00-04:00,AEZS,positive
38497.0,"Aeterna Zentaris Names David Dodd as Chair, Says May Sell Up to 14M Shares for Up to $15M",2014-05-12 07:31:00-04:00,AEZS,positive
38498.0,Aeterna Zentaris Reports Q4 Loss from Continuing Operations $0.28/Share,2014-03-20 16:34:00-04:00,AEZS,negative
38499.0,AEterna Zentaris Inc. Reports Q4 EPS of $(0.22) vs $(0.04) Est,2014-03-20 16:31:00-04:00,AEZS,neutral
38500.0,Morning Market Losers ,2014-01-09 10:10:00-05:00,AEZS,negative
38501.0,"Aeterna Zentaris Announces Proposed Unit Offering; Pricing, Number of Units to be Determined",2014-01-08 16:14:00-05:00,AEZS,positive
38502.0,Aeterna Zentaris NDA for Macimorelin Acetate in AGHD Accepted  for Filing by FDA ,2014-01-06 12:03:00-05:00,AEZS,positive
38503.0,Aeterna Zentaris Names Dr. Richard Sachse as Chief Scientific Officer ,2014-01-03 07:39:00-05:00,AEZS,neutral
38504.0,Seeking Alpha: ' Aeterna Zentaris: Mispriced $1 Biotech Stock With Limited Downside Risk And Big Upside Potential',2013-12-12 13:18:00-05:00,AEZS,negative
38505.0,Stocks Hitting 52-Week Lows,2013-11-20 10:15:00-05:00,AEZS,negative
38506.0,Morning Market Losers ,2013-11-20 09:58:00-05:00,AEZS,negative
38507.0,Aeterna Zentaris Prices 13.1M Unit Offering at $1.15/Unit,2013-11-20 08:29:00-05:00,AEZS,neutral
38508.0,Aeterna Zentaris Closes Transfer of Cetrotide Rights to Merck,2013-10-01 07:33:00-04:00,AEZS,neutral
38509.0,Aeterna Zentaris Reports Listing Transfer to NASDAQ Capital Market,2013-08-28 10:00:00-04:00,AEZS,neutral
38510.0,"AEterna Zentaris Inc. Reports Q2 EPS of $0.37, Up 54% YOY; Revenue of $30.10M, Up 303% YOY",2013-08-08 16:35:00-04:00,AEZS,neutral
38511.0,Stocks Hitting 52-Week Lows,2013-07-25 10:04:00-04:00,AEZS,negative
38512.0,Aeterna Zentaris to Sell 5.2M Shares at $1.50/Share,2013-07-25 09:21:00-04:00,AEZS,positive
38513.0,Euro Pacific Initiates Coverage on AEterna Zentaris Inc. at Hold,2013-07-25 09:07:00-04:00,AEZS,neutral
38514.0,Aeterna Zentaris Announces Election of Directors at its Annual Meeting of Shareholders,2013-05-08 16:06:00-04:00,AEZS,neutral
38515.0,AEterna Zentaris Inc. Reports Q1 EPS of $(0.07) vs $(0.29) Est; Revenue of $16.60M vs $8.34M Est,2013-05-07 16:46:00-04:00,AEZS,neutral
38516.0,Aeterna Zentaris to Transfer Manufacturing Rights for Cetrotide to Merck,2013-04-17 07:34:00-04:00,AEZS,neutral
38517.0,"Aeterna Zentaris Names David Dodd Pres, CEO",2013-04-15 08:07:00-04:00,AEZS,neutral
38518.0,Aeterna Zentaris Issues Encouraging Updated Data on LHRH Receptor-Targeted Disorazol Z Cytotoxic Conjugates,2013-04-10 17:44:00-04:00,AEZS,positive
38519.0,AEterna Zentaris Inc. Reports Q4 EPS of $(0.29) vs $(0.31) Est; Revenue of $9.55M vs $7.96M Est,2013-03-21 16:20:00-04:00,AEZS,neutral
38520.0,"Earnings Scheduled For March 21, 2013",2013-03-21 06:56:00-04:00,AEZS,neutral
38521.0,"Aeterna Zentaris Shares Resume Trading, Now Down 8%",2013-03-11 11:45:00-04:00,AEZS,positive
38522.0,Shares of Aeterna Zentaris to Resume Trade at 11:45AM EST,2013-03-11 11:17:00-04:00,AEZS,positive
38523.0,UPDATE: Aeterna Zentaris to Discontinue Phase 3 Trial in Multiple Myeloma with Perifosine,2013-03-11 11:17:00-04:00,AEZS,neutral
38524.0,Aeterna Zentaris to Discontinue Phase 3 Trial in Multiple Myeloma with perifosine Amid Data Safety Monitoring Board Recommendation,2013-03-11 11:16:00-04:00,AEZS,positive
38525.0,Aeterna Zentaris Halted News Pending,2013-03-11 11:11:00-04:00,AEZS,neutral
38526.0,McNicoll Lewis Vlak Upgrades AEterna Zentaris Inc. to Buy,2013-01-03 09:04:00-05:00,AEZS,neutral
38527.0,"UPDATE: Canaccord Genuity Reiterates Hold Rating, Raises PT on AEterna Zentaris",2012-12-31 08:35:00-05:00,AEZS,neutral
38528.0,"Canaccord Genuity Maintains Hold on AEterna Zentaris Inc., Raises PT to $2.50",2012-12-31 07:38:00-05:00,AEZS,neutral
38529.0,Mid-Day Market Movers,2012-12-28 11:48:00-05:00,AEZS,neutral
38530.0,Benzinga's Top Pre-Market Gainers,2012-12-28 08:14:00-05:00,AEZS,positive
38531.0,Aeterna Zentaris Wins FDA Special Protocol Assessment for Phase 3 Registration Trial in Endometrial Cancer with AEZS-108,2012-12-28 07:57:00-05:00,AEZS,positive
38532.0,Aeterna Zentaris Granted SPA by FDA for Phase 3 AEZS-108 Registration Trial in Endometrial Cancer,2012-12-28 07:36:00-05:00,AEZS,negative
38533.0,Benzinga's Top Pre-Market Gainers,2012-12-11 08:17:00-05:00,AEZS,positive
38534.0,Aeterna Zentaris: Final Phase 2 Data Demonstrate Perifosine and Sorafenib Combination Therapy Well Tolerated by Heavily Pretreated Lymphoma Patients,2012-12-11 07:31:00-05:00,AEZS,positive
38535.0,Aeterna Zentaris Announces Final Phase 2 Data for Perifosine in Lymphomas to be Presented at Upcoming ASH Meeting ,2012-11-26 07:35:00-05:00,AEZS,neutral
38536.0,Aeterna Zentaris Reports Q3 EPS $-0.35 vs $-0.43 Est; Revenues $7.1M vs $8.38M Est,2012-11-13 16:31:00-05:00,AEZS,neutral
38537.0,Aeterna Zentaris Presents Promising Results for Disorazol Z Cytotoxic Conjugates,2012-11-08 08:25:00-05:00,AEZS,positive
38538.0,Stocks Hitting 52-Week Lows,2012-10-22 10:12:00-04:00,AEZS,negative
38539.0,Aeterna Zentaris Regains Compliance with NASDAQ $1.00 Minimum Bid Price Rule ,2012-10-22 07:37:00-04:00,AEZS,neutral
38540.0,Aeterna Zentaris Announces Closing of $16.5 Million Public Offering of Common Shares and Warrants,2012-10-17 09:25:00-04:00,AEZS,positive
38541.0,FDA Considering Faster Pathway for Treatments of Deadly or Debilitating Diseases ,2012-10-17 08:21:00-04:00,AEZS,neutral
38542.0,"Bloom Burton & Co.  Maintains Aeterna Zentaris at Sell, Lowers PT from $2.25 to $2",2012-10-12 11:01:00-04:00,AEZS,negative
38543.0,Aeterna Zentaris Announces Pricing of US $16.5 Million Public Offering of Common Shares and Warrants,2012-10-12 08:57:00-04:00,AEZS,positive
38544.0,Benzinga's Top Pre-Market Losers,2012-10-12 08:22:00-04:00,AEZS,negative
38545.0,Aeterna Zentaris Announces Proposed Public Offering of Common Shares and Warrants,2012-10-11 16:14:00-04:00,AEZS,positive
38546.0,Aeterna Zentaris Granted Patent by European Patent Office for AEZS-130,2012-09-25 07:34:00-04:00,AEZS,positive
38547.0,"Benzinga's Microcap Movers for Thursday September 20, 2012",2012-09-20 19:56:00-04:00,AEZS,neutral
38548.0,Aeterna Zentaris Spikes Higher,2012-08-24 15:44:00-04:00,AEZS,neutral
38549.0,"Benzinga's Microcap Movers for Monday August 14, 2012",2012-08-14 17:47:00-04:00,AEZS,neutral
38550.0,Aeterna Zentaris Reports Q2 EPS $0.04 vs $-0.06 Est,2012-08-14 17:03:00-04:00,AEZS,neutral
38551.0,Aeterna Zentaris Granted Patent in the U.S. for AEZS-130 as Diagnostic Test for Adult Growth Hormone Deficiency ,2012-08-07 07:33:00-04:00,AEZS,positive
38553.0,Aeterna Zentaris Requests Fast Track Designation from the FDA for AEZS-130 as Diagnostic Test for Adult Growth Hormone Deficiency ,2012-07-24 08:41:00-04:00,AEZS,positive
38554.0,Aeterna Zentaris and Partner Yakult Initiates Phase 1 Trial in Multiple Myeloma with Perifosine in Japan ,2012-06-28 07:31:00-04:00,AEZS,neutral
38555.0,"Benzinga's Microcap Movers for Tuesday June 26, 2012",2012-06-26 17:09:00-04:00,AEZS,neutral
38556.0,Aeterna Zentaris Announces Final Phase 3 Results for AEZS-130 in Adult Growth Hormone Deficiency Presented at ENDO Meeting ,2012-06-26 07:31:00-04:00,AEZS,positive
38557.0,Aeterna Zentaris: Phase 1 Results Show Perifosine's Activity Against Neuroblastoma ,2012-06-21 07:31:00-04:00,AEZS,neutral
38558.0,Aeterna Zentaris Learns of Class Action Lawsuits Filed and Denies Allegations ,2012-06-19 07:30:00-04:00,AEZS,negative
38559.0,Aeterna Zentaris Announces Phase 1 Data for Perifosine in Multiple Myeloma Published in the British Journal of Haematology ,2012-06-05 07:31:00-04:00,AEZS,neutral
38560.0,Aeterna Zentaris Receives Notification from NASDAQ Relating to Minimum Bid Price ,2012-05-16 16:16:00-04:00,AEZS,neutral
38561.0,Aeterna Zentaris Regains North American Rights for Perifosine from Keryx ,2012-05-07 07:36:00-04:00,AEZS,neutral
38562.0,Aeterna Zentaris Regains North American Rights for Perifosine from Keryx ,2012-05-07 07:31:00-04:00,AEZS,neutral
38563.0,"Oppenheimer Downgrades Aeterna Zentaris from Outperform to Perform, Removes PT",2012-04-02 13:55:00-04:00,AEZS,neutral
38564.0,Morning Market Losers,2012-04-02 10:07:00-04:00,AEZS,negative
38565.0,Keryx Biopharmaceuticals Falls 58% on Failed Phase 3 Results,2012-04-02 07:33:00-04:00,AEZS,negative
38566.0,"Keryx Biopharmaceuticals, Aeterna Zentaris Resume Trading",2012-04-02 07:30:00-04:00,AEZS,neutral
38567.0,A Peek Into The Market Before The Trading Starts,2012-04-02 07:28:00-04:00,AEZS,neutral
38568.0,"PREVIEW: Keryx Biopharmaceuticals, AEterna Zentaris to Resume Trading at 7:30am",2012-04-02 07:18:00-04:00,AEZS,neutral
38569.0,Aeterna Zentaris Announces Top-Line Data from the Perifosine Phase 3 Trial in Refractory Advanced Colorectal Cancer; Did not Meet Primary Endpoint   ,2012-04-02 07:05:00-04:00,AEZS,negative
38570.0,AEterna Zentaris Reports Q4 $(0.07) vs $(0.09) Est; Revs $12.6M vs $7.78M Est,2012-03-27 16:17:00-04:00,AEZS,neutral
38571.0,"Michael E. DeBakey VA Medical Center Initiates Phase 2A Trial in Cancer Cachexia with Aeterna Zentaris' Ghrelin Agonist, AEZS-130 ",2012-03-08 07:31:00-05:00,AEZS,negative
38572.0,Keryx Biopharma Trade Lower after Adam Feuerstein's Negative Blog Post,2012-03-06 07:47:00-05:00,AEZS,negative
38573.0,Aeterna Zentaris Trading 17.7% Higher on Heavy Volume; Currently at $2.06,2012-03-05 10:04:00-05:00,AEZS,neutral
38574.0,Aeterna Zentaris Reports Updated Phase 1 Trial Results for AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer; Demonstrated Early Evidence of Antitumor Activity  ,2012-02-03 07:39:00-05:00,AEZS,negative
38575.0,Aeterna Zentaris Spiking Higher,2012-01-31 14:25:00-05:00,AEZS,neutral
38576.0,Scorecard and New Picks: Technical Value Fishing Under $5,2012-01-26 07:18:00-05:00,AEZS,positive
38577.0,Oppenheimer Reduces AEterna Zentaris PT,2012-01-24 17:31:00-05:00,AEZS,neutral
38578.0,"Aeterna Zentaris Announces ""At-the-Market"" Issuance Program of up to $16M",2012-01-24 07:16:00-05:00,AEZS,neutral
38579.0,Aeterna Zentaris Announces Collaboration with Ventana Medical Systems to Develop Companion Diagnostic in Cancer for AEZS-108 ,2012-01-05 07:31:00-05:00,AEZS,negative
38580.0,"Aeterna Zentaris Partner, Yakult Honsha, Initiates Phase 1/2 Trial with Perifosine in Colorectal Cancer in Japan ",2012-01-03 07:30:00-05:00,AEZS,negative
38581.0,Aeterna Zentaris Announces Encouraging Clinical Data for Perifosine in Hodgkin Lymphoma Presented at ASH Meeting ,2011-12-13 08:02:00-05:00,AEZS,positive
38582.0,Aeterna Zentaris Announces Encouraging Preclinical Data for Perifosine in Hodgkin Lymphoma Presented at ASH Meeting ,2011-12-12 08:02:00-05:00,AEZS,positive
38583.0,"Aeterna Zentaris Presents Positive Preclinical Data in Breast Cancer on AEZS-131,",2011-12-09 07:31:00-05:00,AEZS,negative
38584.0,Aeterna Zentaris: FDA Grants IND to Investigator at Baylor College of Medicine for Phase 2A Trial with AEZS-130 in Cancer Cachexia ,2011-11-28 07:31:00-05:00,AEZS,negative
38585.0,"Financial Breakfast: Morning News Summary for November 23, 2011",2011-11-23 07:48:00-05:00,AEZS,neutral
38586.0,"Aeterna Zentaris and Hikma Pharmaceuticals Sign a Commercialization and Licensing Agreement for Lead Oncology Compound, Perifosine, for Middle East and North Africa Region  ",2011-11-23 07:31:00-05:00,AEZS,positive
38587.0,Aeterna Zentaris Presents Encouraging Preclinical Data for Disorazol Z at AACR-NCI-EORTC Conference ,2011-11-16 07:31:00-05:00,AEZS,positive
38588.0,"Rodman & Renshaw Reiterates Outperform, $3 PT on Aeterna Zentaris  ",2011-11-14 08:58:00-05:00,AEZS,neutral
38589.0,Oppenheimer Outperform on AEterna Zentaris ,2011-11-10 14:50:00-05:00,AEZS,neutral
38590.0,Aeterna Zentaris Chatter from Seeking Alpha Post,2011-10-27 12:33:00-04:00,AEZS,neutral
38591.0,Aeterna Zentaris Spiking Higher on Takeover Chatter,2011-10-27 12:29:00-04:00,AEZS,neutral
38592.0,Aeterna Zentaris: FDA Grants IND to Investigator at University of Miami School of Medicine for Phase 2 Trial with AEZS-108 in Triple-Negative Breast Cancer  ,2011-10-25 07:33:00-04:00,AEZS,negative
38593.0,Keryx Biopharmaceuticals Announces Phase 1 / 2 Clinical Trial Results of KRX-0401 Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Published in the Journal of Clinical Oncology ,2011-10-13 09:35:00-04:00,AEZS,neutral
38594.0,Aeterna Zentaris: Journal of Clinical Oncology Publishes Phase 2 Clinical Trial Results of Perifosine Plus Capecitabine in Patients with Metastatic Colorectal Cancer ,2011-10-05 08:38:00-04:00,AEZS,negative
38595.0,Aeterna Zentaris Announces Interim Data for its Phase 1/2 Trial with AEZS-108 in Prostate Cancer at ESMO Congress; AEZS-108 well tolerated at all dose levels / Early evidence of anti-tumor activity ,2011-09-26 07:01:00-04:00,AEZS,negative
38596.0,Rodman & Renshaw Outperform on Æterna Zentaris,2011-09-15 14:07:00-04:00,AEZS,neutral
38597.0,"Rodman & Renshaw Reiterates Aeterna Zentaris Market Outperform, $3 PT",2011-09-01 13:06:00-04:00,AEZS,neutral
38598.0,Aeterna Zentaris Announces Completion of Interim Analysis by Data Safety Monitoring Board for the Phase 3 Study of Perifosine for the Treatment of Refractory Advanced Colorectal Cancer ,2011-08-31 08:35:00-04:00,AEZS,negative
38599.0,"McNicoll, Lewis & Vlak Maintains Aeterna Zentaris Buy, PT",2011-08-30 15:41:00-04:00,AEZS,neutral
38600.0,Aeterna Zentaris Announces Favorable Top-Line Results of Completed Phase 3 Study on AEZS-130 ,2011-08-30 08:32:00-04:00,AEZS,positive
38601.0,Aeterna Zentaris Announces Results of its Novel Orally Active Anticancer Erk Inhibitor at the American Chemical Society National Meeting ,2011-08-30 07:30:00-04:00,AEZS,positive
38602.0,Desjardins Upgrades AEterna Zentaris to Buy From Hold,2011-08-09 09:19:00-04:00,AEZS,neutral
38603.0,Desjardins Upgrades AEZS To Buy,2011-08-09 09:18:00-04:00,AEZS,neutral
38605.0,Aeterna Zentaris Announces Completion of Patient Recruitment for Phase 3 Trial with Perifosine in Refractory Advanced Colorectal Cancer  ,2011-07-27 08:36:00-04:00,AEZS,negative
38606.0,Aeterna Zentaris Completes Phase 3 Study on AEZS-130 as First Oral Diagnostic Test for Adult Growth Hormone Deficiency  ,2011-07-26 13:31:00-04:00,AEZS,positive
38607.0,"Aeterna Zentaris Successfully Reached a Key Milestone in the Non-Clinical Development of its Oral Prostate Cancer Vaccine Candidate, AEZS-120  ",2011-07-20 07:32:00-04:00,AEZS,negative
38608.0,Aeterna Zentaris Announces Poster Presentation on Final Phase 2 Results for AEZS-108 in Endometrial Cancer at Upcoming ESGO Meeting,2011-07-18 07:32:00-04:00,AEZS,negative
38609.0,A Peek Into The Market Before The Trading Starts,2011-07-12 07:58:00-04:00,AEZS,neutral
38610.0,Aeterna Zentaris Granted Patent for Perifosine by European Patent Office ,2011-07-12 07:31:00-04:00,AEZS,positive
38611.0,"Aeterna Zentaris Announces ""At-the-Market"" Issuance Program to Sell up 9.5M Shares",2011-06-29 16:17:00-04:00,AEZS,positive
38612.0,"Oppenehimer Initiates AEterna Zentaris At Outperform, $5.50 PT",2011-06-07 07:11:00-04:00,AEZS,neutral
38613.0,"Aeterna Zentaris Announces Results on AEZS-131, a Highly Selective Erk 1/2 Inhibitor Anticancer Compound at American Association for Cancer Research Annual Meeting ",2011-04-05 08:03:00-04:00,AEZS,negative
38614.0,Aeterna Zentaris Announces Results On Its Lead Anticancer Agent Perifosine at American Association for Cancer Research Annual Meeting ,2011-04-04 13:02:00-04:00,AEZS,negative
38615.0,Aeterna Zentaris Awarded Grant by German Government to Develop Novel Targeted Anti-Cancer Compounds ,2011-03-24 07:37:00-04:00,AEZS,positive
38616.0,Aeterna Zentaris Reports Q4 EPS of $(0.03) vs. $(0.07),2011-03-22 10:29:00-04:00,AEZS,neutral
38617.0,A Peek Into The Market Before The Trading Starts,2010-12-20 07:59:00-05:00,AEZS,neutral
38618.0,Aeterna Zentaris Receives Agreement from FDA on Special Protocol Assessment for Solorel ,2010-12-20 07:39:00-05:00,AEZS,positive
38619.0,Aeterna Zentaris to Present Phase 2 Results for AEZS-108 at Major Conference ,2010-11-10 07:57:00-05:00,AEZS,neutral
38620.0,Aeterna Zentaris Reports Third Quarter EPS of $(0.12),2010-11-09 12:44:00-05:00,AEZS,neutral
38621.0,Aeterna Zentaris Announces Orphan Drug AEZS-130 Interim Phase 3 Data Analysis Shows Potential for 2011 Filing ,2010-10-05 13:05:00-04:00,AEZS,neutral
38622.0,"Top Day Trader Alerts (AEZS, AMSC, APCVZ, DBTK, HAUP, LOW, HD, OSIP, SIRI, TIVO)",2010-05-17 08:57:00-04:00,AEZS,negative
38623.0,"Benzinga’s Top Pre-Market Gainers (NLST, AEZS, SCLN, BPAX, TIVO)",2010-05-17 08:27:00-04:00,AEZS,positive
38624.0,"Top Analyst Upgrades and Downgrades (AEZS, ACV, MDRX, CAAS, DELL, HPQ, BEE, SIMG, SY, TEF, TIVO, WCRX)",2010-05-17 08:22:00-04:00,AEZS,positive
38625.0,AEterna (AEZS) Pares Down Its Losses,2010-05-13 16:13:00-04:00,AEZS,negative
38626.0,"Market Roundup (IBM, SBUX, MCD, AEZS, MBLX)",2010-05-12 15:08:00-04:00,AEZS,neutral
38627.0,"Benzinga’s Top Pre-Market Gainers (SMTX, NLST, ACHN, AEZS, VICL)",2010-05-12 09:02:00-04:00,AEZS,positive
38628.0,"Keryx Drug Is On “Fast-Track” (KERX, AEZS)",2010-04-06 16:14:00-04:00,AEZS,neutral
38629.0,"Market Roundup (KERX, AEZS, PEP, BUD, GOOG, BRK.A, FRE, ZION, RF, MTB)",2010-04-05 15:19:00-04:00,AEZS,neutral
38630.0,"Benzinga’s Top Pre-Market Gainers (AEZS, ADBE, MF, NVAX)",2010-03-24 08:10:00-04:00,AEZS,positive
38631.0,Aeterna Zentaris Inc. (AEZS) Going Strong,2009-12-10 16:10:00-05:00,AEZS,positive
38632.0,"Today's Morning Top Gainers (SPEX,KERX,ACAS,AEZS,DARA)",2009-09-16 12:07:00-04:00,AEZS,positive
